A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
NCT01212276
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
18
Enrollment
INDUSTRY
Sponsor class
Stopped
Sponsor terminated protocol
Conditions
Metastatic Melanoma
Malignant Metastatic Melanoma
Advanced Melanoma
Melanoma
Interventions
DRUG:
MORAb-028
Sponsor
Morphotek